Payment overview · 2025
General Payments
$389.02
3 reported records · 2 companies
Healthcare provider profile · identity verified
Jose E Mendoza, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AVON, OH · NPI 1578533659
Verified facts
What the public records show
CMS Open Payments records show Jose E Mendoza, M.D. received $389.02 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 64.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $249.12 | 64.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $139.90 | 36.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $389.02 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $139.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.36 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 822 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 621 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 548 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 458 | 101 |
| Losartan Potassium | Losartan Potassium | 444 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 434 | 107 |
| Omeprazole | Omeprazole | 431 | 98 |
| Lisinopril | Lisinopril | 408 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 407 | 97 |
| Gabapentin | Gabapentin | 344 | 62 |
| Metformin Hcl | Metformin Hcl | 337 | 81 |
| Ibuprofen | Ibuprofen | 323 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 290 | 61 |
| Alprazolam | Alprazolam | 276 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 255 | 80 |
| Simvastatin | Simvastatin | 236 | 59 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 234 | 54 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 228 | 52 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 226 | 64 |
| Trazodone Hcl | Trazodone Hcl | 214 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 69 |
| Potassium Chloride | Potassium Chloride | 206 | 45 |
| Allopurinol | Allopurinol | 200 | 51 |
| Meloxicam | Meloxicam | 191 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 48 |
| Furosemide | Furosemide | 184 | 51 |
| Montelukast Sodium | Montelukast Sodium | 180 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 24 |
| Glimepiride | Glimepiride | 161 | 29 |
| Tramadol Hcl | Tramadol Hcl | 157 | 37 |
| Ozempic | Semaglutide | 155 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 34 |
| Levofloxacin | Levofloxacin | 151 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 39 |
| Atenolol | Atenolol | 149 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 143 | 33 |
| Diazepam | Diazepam | 137 | 24 |
| Azithromycin | Azithromycin | 130 | 87 |
| Ipratropium Bromide | Ipratropium Bromide | 128 | 61 |
| Jardiance | Empagliflozin | 125 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 124 | 17 |
| Pregabalin | Pregabalin | 116 | 20 |
| Valsartan | Valsartan | 116 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 21 |
| Prednisone | Prednisone | 110 | 45 |
| Paroxetine Hcl | Paroxetine Hcl | 107 | 21 |
| Sertraline Hcl | Sertraline Hcl | 104 | 24 |
| Carvedilol | Carvedilol | 103 | 27 |
| Famotidine | Famotidine | 100 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 36 |
| Buspirone Hcl | Buspirone Hcl | 91 | 18 |
| Fluconazole | Fluconazole | 90 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 22 |
| Lorazepam | Lorazepam | 83 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 45 |
| Mirtazapine | Mirtazapine | 79 | suppressed |
| Eliquis | Apixaban | 78 | 18 |
| Alendronate Sodium | Alendronate Sodium | 74 | 18 |
| Trulicity | Dulaglutide | 74 | suppressed |
| Bupropion Xl | Bupropion Hcl | 73 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 70 | 13 |
| Valacyclovir | Valacyclovir Hcl | 65 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 14 |
| Donepezil Hcl | Donepezil Hcl | 64 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 64 | 13 |
| Clonidine Hcl | Clonidine Hcl | 63 | 17 |
| Metformin Hcl Er | Metformin Hcl | 63 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 17 |
| Methylprednisolone | Methylprednisolone | 62 | 50 |
| Cefuroxime | Cefuroxime Axetil | 60 | 46 |
| Ezetimibe | Ezetimibe | 59 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 46 |
| Nystatin | Nystatin | 58 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 15 |
| Amoxicillin | Amoxicillin | 57 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 47 |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | suppressed |
| Naproxen | Naproxen | 54 | 13 |
| Mometasone Furoate | Mometasone Furoate | 53 | 19 |
| Januvia | Sitagliptin Phosphate | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Finasteride | Finasteride | 49 | 15 |
| Meclizine Hcl | Meclizine Hcl | 48 | 22 |
| Synthroid | Levothyroxine Sodium | 48 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 11 |
| Lovastatin | Lovastatin | 47 | 12 |
| Mupirocin | Mupirocin | 47 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Clonazepam | Clonazepam | 45 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 26 |
| Ketoconazole | Ketoconazole | 45 | 14 |
| Linzess | Linaclotide | 45 | suppressed |
| Celecoxib | Celecoxib | 44 | 14 |
| Sucralfate | Sucralfate | 43 | 16 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 12 |
| Nitroglycerin | Nitroglycerin | 32 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Colchicine | Colchicine | 22 | 11 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 12 |
| Vyvanse | Lisdexamfetamine Dimesylate | 21 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 11 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Dasetta | Norethindrone-Ethin. Estradiol | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $389.02 · 3 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, INSPIRE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error